UNSPSC 51141578: Rufinamide

This classification denotes an anticonvulsant agent with the molecular formula C10H8F2N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WFW942PR79, chemically known as 1h-1,2,3-triazole-4-carboxamide, 1-((2,6-difluorophenyl)methyl)- but generally known as rufinamide, which bears US NIH Compound Identifier 129228. European Medicines Agency schedules Rufinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10403MIG.

UNSPSC 51141578 Rufinamide is a Commodity code that nominally covers a single anticonvulsant pharmaceutical product, but recent state and local procurement activity under this code does not show targeted solicitations for rufinamide itself. Instead, the opportunities tagged to this code reflect broader pharmaceutical procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. The mismatch between the code's nominal scope and actual buying signals suggests that state and local procurement offices are using this code as a catch-all for pharmaceutical products and related health-related goods rather than applying it to discrete drug identities. What is actually being bought under the code includes emergency medical supplies (naloxone), pharmaceutical sourcing infrastructure and vendor management, and generic drug distribution through authorized wholesalers.

Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon). The most recent activity spans Florida, Texas, and the Upper Midwest. Representative opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, posted June 30, 2026, with a response deadline of July 26, 2023; Texas HHS's RFI on direct-to-manufacturer prescription programs, posted April 3, 2026, exploring vendor capabilities for bypassing traditional pharmacy benefit managers; and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with a response deadline of March 26, 2026, requiring vendors to supply through three authorized wholesalers and agreeing to a 3 percent administrative fee, with contract effectiveness July 1, 2026. The MMCAP solicitation emphasizes price competitiveness (75 percent evaluation weight), EDI capability, and compliance with cGMP and Drug Supply Chain Security Act standards.